• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

Palatin to submit LeuTech application

Article

After a successful meeting with the Food and Drug Administration last month, biopharmaceutical firm Palatin Technologies got the go-ahead to file a biologics license application this summer for its monoclonal antibody infection imaging agent,

After a successful meeting with the Food and Drug Administration last month, biopharmaceutical firm Palatin Technologies got the go-ahead to file a biologics license application this summer for its monoclonal antibody infection imaging agent, LeuTech. The company met with the FDA’s Center for Biologic Evaluation and Research in Rockville, MD, and the agency reviewed Palatin’s phase III trial data for LeuTech for the diagnosis of equivocal appendicitis. Palatin hopes LeuTech will be available for sale by mid-summer 2000.

The FDA’s permission to proceed further enhances the Princeton, NJ, company’s R&D momentum, as it comes on the heels of the company’s May 17 announcement that it had signed a letter of intent for a marketing alliance with St. Louis-based Mallinckrodt (SCAN 5/26/99).

© 1999 Miller Freeman, Inc.All rights reserved.

Related Videos
Where the USPSTF Breast Cancer Screening Recommendations Fall Short: An Interview with Stacy Smith-Foley, MD
A Closer Look at MRI-Guided Transurethral Ultrasound Ablation for Intermediate Risk Prostate Cancer
Improving the Quality of Breast MRI Acquisition and Processing
Can Fiber Optic RealShape (FORS) Technology Provide a Viable Alternative to X-Rays for Aortic Procedures?
Does Initial CCTA Provide the Best Assessment of Stable Chest Pain?
Making the Case for Intravascular Ultrasound Use in Peripheral Vascular Interventions
Can Diffusion Microstructural Imaging Provide Insights into Long Covid Beyond Conventional MRI?
Assessing the Impact of Radiology Workforce Shortages in Rural Communities
Emerging MRI and PET Research Reveals Link Between Visceral Abdominal Fat and Early Signs of Alzheimer’s Disease
Reimbursement Challenges in Radiology: An Interview with Richard Heller, MD
Related Content
© 2024 MJH Life Sciences

All rights reserved.